Zhitong Finance App News, Shiyao Innovation (300765.SZ) announced that the company's holding subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as “Jushi Biology”), announced the Phase I clinical study data of SYS6002 monotherapy for the treatment of advanced cervical cancer in the form of a quick oral report at the 2026 International Society of Gynecological Oncology Global Meeting (IGCS Annual Global Meeting) held in Montreal, Canada from October 1 to October 3.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.